Assistant Professor
Ph.D. (Medicine)
HAYASHI Hironori
Organization
Research Division
- Risk Evaluation and Disaster Mitigation Research Division
- Disaster Humanities and Social Science Division
- Disaster Medical Science Division
- Practical Research and Collaboration Division
- Endowed Research Division
- Joint Research Division
- Co-creation Center for Disaster Resilience
- Global Centre for Disaster Statistics
- Kesennuma Satellite Office
- Public Relations Office
- Administration Office
- Research Subject(s)
- Novel coronavirus (SARS-CoV-2) outbreak and antimicrobial resistance are impacting global health and show importance of novel therapeutics. Our research themes are the development of novel drugs for infectious diseases. Additionally, we analyze the mechanisms of drug resistance and the intermolecular interactions between compounds and proteins.
- Key Words
- outbreak / drug resistance / drug development / Antiviral drug / Antibacterial drug
- Research Activities
-
Development of novel therapeutics for human immunodeficiency virus infection
Using X-ray crystal structural analyses, we identified important interactions, which play key roles in highly potent activity of the novel compounds against both wild-type and drug-resistant HIV-1 strains and their substantially high genetic barrier.Development of novel antibacterial compounds
We identified novel antibacterial drugs and analyzed their antibacterial mechanisms. - Selected Works
-
Oe C, et al. (2020) Pyrimidine analogs as a new class of Gram-positive antibiotics, mainly targeting thymineless-death related proteins. ACS Infectious Diseases, 6(6), 1490, doi: 10.1021/acsinfecdis.9b00305.
Tsukada K, et al. (2020) Synthetic biology based construction of biological activity-related library of fungal decalin-containing diterpenoid pyrones. Nature Communications, 11(1), 1830, doi: 10.1038/s41467-020-15664-4
Aoki M, et al. (2017) A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency. eLife, 6, e28020. doi:10.7554/eLife.28020.
Aoki M, et al. (2015) C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir. Journal of Virology, 90(5), 2180.
Hayashi H, et al. (2014) Dimerization of HIV-1 Protease Occurs through Two Steps Relating to the Mechanism of Protease Dimerization Inhibition by Darunavir. Proceedings of the National Academy of Sciences of the United States of America, 111(33), 12234, doi:10.1073/pnas.1400027111